AstraZeneca’s Lokelma Receives FDA’s Approval for Patients with Hyperkalaemia in Adults

AstraZeneca and Merck Report Result of Lynparza (olaparib) in P-III POLO Trial for BRCA-Mutated Metastatic Pancreatic Cancer #ASCO2019


  • The approval is based on five studies assessing Lokelma vs PBO in patients with hyperkalaemia
  • The study resulted in onset of action was at 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, 92% of patients achieved normal potassium level in 48 hrs. and was effective for 12 mos.
  • Lokelma insoluble, non-absorbed sodium zirconium silicate formerly known as ZS-9, and has received EU’s approval on 22 Mar,2018

Click here to read full press release/ article | Ref: AstraZeneca | Image: Pharma